Concepedia

Stacie Canan

SC

Statistics

Publications

9

Citations

627

H-Index

9

Active since

2007

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

Stacie Canan is an author at Bristol-Myers Squibb (Switzerland) specializing in pharmacology, drug discovery, and pharmacy.

Publications per year

2007–2023

9

Publications

9

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D. Thomas, Christopher Calabrese, Michael A. Batey et al. · Molecular Cancer Therapeutics · 2007 · 302 citations

, , +15

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Deborah S. Mortensen, Sophie Perrin-Ninkovic, Graziella Shevlin et al. · Journal of Medicinal Chemistry · 2015 · 73 citations · Full text

, , +14

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Jennifer R. Riggs, Mark A. Nagy, Jan Elsner et al. · Journal of Medicinal Chemistry · 2017 · 60 citations · Full text

, , +13

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization

Deborah S. Mortensen, Kimberly E. Fultz, Shuichan Xu et al. · Molecular Cancer Therapeutics · 2015 · 53 citations · Full text

, , +14

Collaborative virtual screening to elaborate an imidazo[1,2- <i>a</i> ]pyridine hit series for visceral leishmaniasis

Yuichiro Akao, Stacie Canan, Yafeng Cao et al. · RSC Medicinal Chemistry · 2021 · 40 citations · Full text

, , +16

1–5 of 9